Rearrangements in KMT2A are present in approximately 20% of children with de novo AML and in 5–10% of adults and are associated with a poor prognosis with higher rates of relapse and resistance to chemotherapy [6,7,12]. Here, KMT2A is linked to acute myeloid leukemia.